Alprazolam

Generic Name: Alprazolam

Brand Names: Niravam, Xanax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₃ClN_₄

CAS Number: 28981-97-7

Unique Ingredient Identifier: YU55MQ3IZY

Background: Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effe...

Indication: Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.

Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.

Associated Conditions: Generalized Anxiety Disorder, Panic Disorder

Associated Therapies: -

Clinical Trials

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Alprazolam Placebo
Drug: Alprazolam
Drug: Cenobamate placebo
Drug: Cenobamate

First Posted Date: 2018-04-26

Last Posted Date: 2024-11-07

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 53

Registration Number: NCT03509285

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc, Overland Park, Kansas, United States
🇨🇦
INC Research, Inc., Toronto, Ontario, Canada

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Phase 1

Completed

Conditions: Cannabis Use Disorder

Interventions: Drug: THC
Drug: Alprazolam
Drug: Placebo oral capsule
Drug: CBD

First Posted Date: 2018-01-12

Last Posted Date: 2018-06-14

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 42

Registration Number: NCT03398083

Locations: 🇺🇸
Debra Kelsh, MD, Overland Park, Kansas, United States

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

Phase 1

Completed

Conditions: Recreational Drug Use
Prescription Drug Abuse (Not Dependent)

Interventions: Drug: Placebo
Drug: Lasmiditan
Drug: Alprazolam

First Posted Date: 2017-09-18

Last Posted Date: 2020-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 96

Registration Number: NCT03286218

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States

The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants

Phase 1

Completed

Conditions: Migraine

Interventions: Other: Placebo
Drug: Alprazolam
Drug: Lasmiditan

First Posted Date: 2017-01-06

Last Posted Date: 2020-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 90

Registration Number: NCT03012334

Locations: 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

Early Phase 1

Conditions: Psychotropic Drugs Effects

Interventions: Drug: Zolpidem
Drug: Alprazolam
Drug: Caffeine
Other: Placebo

First Posted Date: 2012-12-11

Last Posted Date: 2012-12-11

Lead Sponsor: Mclean Hospital

Target Recruit Count: 12

Registration Number: NCT01747590

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Spectroscopic Imaging at 4T: A Drug Challenge Study

Not Applicable

Terminated

Conditions: AOD Effects and Consequences

Interventions: Other: Placebo
Drug: Alprazolam
Drug: Dextroamphetamine

First Posted Date: 2012-04-16

Last Posted Date: 2017-04-04

Lead Sponsor: Mclean Hospital

Target Recruit Count: 7

Registration Number: NCT01577706

Locations: 🇺🇸
McLean Imaging Center, McLean Hospital, Belmont, Massachusetts, United States

Reassessment of Premedication in Surgery

Phase 4

Completed

Conditions: Anxiety

Interventions: Drug: placebo
Drug: Alprazolam
Drug: Zopiclone

First Posted Date: 2012-03-09

Last Posted Date: 2013-09-25

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 455

Registration Number: NCT01549691

Locations: 🇫🇷
Dept of Anesthesia, Hôpital Foch,, Suresnes, Ile de France, France
🇫🇷
Dept of Anesthesia, Hôpital Tenon, Paris, Ile de France, France
🇫🇷
Clinique St Leonard, Trélazé, Maine et Loire, France

and more 5 locations

Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block

Phase 4

Completed

Conditions: Inferior Alveolar Nerve Block Failure

Interventions: Drug: placebo
Drug: Alprazolam

First Posted Date: 2012-03-07

Last Posted Date: 2012-03-07

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT01546090

Locations: 🇮🇷
School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of

Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder

Phase 4

Withdrawn

Conditions: Anxiety Disorder

Interventions: Drug: buspirone+alprazolam
Drug: alprazolam

First Posted Date: 2012-03-07

Last Posted Date: 2015-05-20

Lead Sponsor: Seoul National University Hospital

Registration Number: NCT01546896

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy